Free Trial
→ They didn't warn anyone in 1971. This time someone is warning you. (From Reagan Gold Group) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
$0.92
-2.8%		$1.02
$0.62
▼
$6.25
$6.24M2.061.26 million shs70,943 shs
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
$0.44
-6.0%		$0.65
$0.43
▼
$3.15
$20.36M0.9340,684 shs31,136 shs
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
$1.27
-10.6%		$2.24
$1.00
▼
$16.25
$22.30M1.7856,962 shs82,302 shs
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$0.30
-7.9%		$0.57
$0.29
▼
$2.57
$21.72M1.15750,792 shs749,895 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
0.00%-8.12%-14.74%-17.70%-70.70%
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
0.00%-2.70%-27.59%-54.12%-64.27%
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
0.00%-13.94%-32.38%-67.36%-77.10%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
0.00%-5.74%-18.14%-69.48%-84.81%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
$0.92
-2.8%		$1.02
$0.62
▼
$6.25
$6.24M2.061.26 million shs70,943 shs
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
$0.44
-6.0%		$0.65
$0.43
▼
$3.15
$20.36M0.9340,684 shs31,136 shs
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
$1.27
-10.6%		$2.24
$1.00
▼
$16.25
$22.30M1.7856,962 shs82,302 shs
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$0.30
-7.9%		$0.57
$0.29
▼
$2.57
$21.72M1.15750,792 shs749,895 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
0.00%-8.12%-14.74%-17.70%-70.70%
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
0.00%-2.70%-27.59%-54.12%-64.27%
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
0.00%-13.94%-32.38%-67.36%-77.10%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
0.00%-5.74%-18.14%-69.48%-84.81%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
2.00
HoldN/AN/A
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
2.00
Hold$8.001,718.18% Upside
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
2.33
Hold$11.00766.14% Upside
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
2.13
Hold$2.67803.04% Upside

Current Analyst Ratings Breakdown

Latest CELZ, RADX, TCRX, and ESLA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/24/2026
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
9/24/2026
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
9/10/2026
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
9/8/2026
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
9/8/2026
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
9/8/2026
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Neutral$1.00
9/2/2026
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Neutral$1.00
9/2/2026
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Lifesci Capital logo
Lifesci Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/27/2026
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/25/2026
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/20/2026
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
Roth Capital logo
Roth Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
(Data available from 10/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
$10K606.28N/AN/A$2.04 per share0.45
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
N/AN/AN/AN/A($0.27) per shareN/A
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
$1.88M10.61N/AN/A$1.28 per share0.99
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$10.32M1.94N/AN/A$2.16 per share0.14
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
-$5.99M-$2.07N/AN/AN/AN/A-86.52%-81.96%11/6/2026 (Estimated)
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
-$13.06M-$0.24N/AN/AN/AN/AN/A-328.72%12/2/2026 (Estimated)
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
-$38.65MN/AN/AN/AN/AN/AN/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$129.77M-$0.91N/AN/AN/A-1,655.35%-108.72%-54.47%11/11/2026 (Estimated)

Latest CELZ, RADX, TCRX, and ESLA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
-$0.09-$0.05+$0.04-$0.05N/AN/A
8/12/2026Q2 2026
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$0.2534-$0.23+$0.0234-$0.23$1.88 million$1.05 million
8/7/2026Q2 2026
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
-$0.39-$0.41-$0.02-$0.41N/AN/A
7/31/2026Q4 2026
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/A-$0.81N/A-$0.8050N/A$0.49 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
N/AN/AN/AN/AN/A
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
N/AN/AN/AN/AN/A
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/AN/AN/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
N/A
12.90
12.90
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
N/A
0.20
0.20
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/A
1.16
1.16
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
0.31
3.37
3.37

Institutional Ownership

CompanyInstitutional Ownership
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
1.42%
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
0.35%
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
82.83%

Insider Ownership

CompanyInsider Ownership
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
1.00%
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
5.80%
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
N/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
6.25%
CompanyEmployeesShares OutstandingFree FloatOptionable
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
46.59 million6.53 millionNot Optionable
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
N/A43.50 million40.98 millionNot Optionable
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
1415.70 millionN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
14267.78 million63.54 millionNot Optionable

Recent News About These Companies

TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock Has Consensus Price Target of $2.67
October 2 at 2:44 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31077096
TScan Therapeutics (NASDAQ:TCRX) Stock Jumps 1% - Here's What Happened
October 2 at 1:41 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31076625
Korro Bio (NASDAQ:KRRO) & TScan Therapeutics (NASDAQ:TCRX) Financial Review
October 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31072982
TScan Therapeutics consensus price target decreased by 55.56% to $2.72
September 16, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/tscan-therapeutics-consensus-price-target-decreased-by-55-56-to-2-72/ar-AA2cjuKv
Wedbush downgrades TScan Therapeutics (TCRX) to neutral from outperform
September 3, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/wedbush-downgrades-tscan-therapeutics-tcrx-to-neutral-from-outperform/ar-AA2bwA9B
TScan Therapeutics Reorganizes To Focus On Solid Tumor Program; To Cut 75% Jobs; Stock Tumbles 11%
September 2, 2026  |  rttnews.comhttps://www.rttnews.com/3687878/tscan-therapeutics-reorganizes-to-focus-on-solid-tumor-program-to-cut-75-jobs-stock-tumbles-11.aspx
TScan Therapeutics cuts workforce by 75% and shifts focus to solid tumor program
September 2, 2026  |  msn.comhttps://www.msn.com/en-us/science/general/tscan-therapeutics-cuts-workforce-by-75-and-shifts-focus-to-solid-tumor-program/ar-AA2bqfIn
TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction
September 2, 2026  |  benzinga.comhttps://www.benzinga.com/news/health-care/26/09/61580674/tscan-reorganizes-pipeline-priorities-implements-workforce-reduction
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
September 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/02/3354974/0/en/tscan-therapeutics-announces-strategic-reorganization-to-focus-on-in-vivo-cell-therapy-for-solid-tumors.html
Analysts Offer Insights on Healthcare Companies: Immix Biopharma (IMMX), TScan Therapeutics (TCRX) and enGene Holdings (ENGN)
August 13, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/IMMX/pressreleases/3830638/analysts-offer-insights-on-healthcare-companies-immix-biopharma-immx-tscan-therapeutics-tcrx-and-engene-holdings-engn/
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates
August 12, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2973293/tscan-therapeutics-inc-tcrx-reports-q2-loss-misses-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2973293
TScan Therapeutics Reports First Patient Dosed in Phase 3 ALLOHA-2 Study and Second-Quarter 2026 Results
August 12, 2026  |  quiverquant.comQ
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/12/3343490/0/en/tscan-therapeutics-reports-second-quarter-2026-financial-results-and-provides-corporate-update.html
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
July 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/29/3335095/0/en/tscan-therapeutics-announces-first-patient-dosed-in-phase-3-alloha-2-a-pivotal-trial-evaluating-tsc-101-in-patients-with-heme-malignancies.html
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
June 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/24/3316713/0/en/tscan-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-cell-therapy-virtual-conference.html
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic ...
June 23, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/tscan-therapeutics-announces-positive-initial-data-from-cohort-c-of-ongoing-alloha-phase-1-study-evaluating-tsc-101-in-patients-with-heme-malignancies-undergoing-allogeneic-hematopoietic-cell-1036264745
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
June 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/22/3315162/0/en/tscan-therapeutics-announces-positive-initial-data-from-cohort-c-of-ongoing-alloha-phase-1-study-evaluating-tsc-101-in-patients-with-heme-malignancies-undergoing-allogeneic-hematop.html
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
June 3, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260603703141/en/cellares-and-tscan-therapeutics-announce-agreement-to-evaluate-automated-manufacturing-of-tsc-101-for-patients-with-hematologic-malignancies/
TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss
June 2, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/tscan-therapeutics-inc-tcrx-reports-q1-2026-results-with-improved-net-loss-1773515/
TScan Therapeutics Expands Authorized Shares After Stockholder Vote
May 22, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/tscan-therapeutics-expands-authorized-shares-after-stockholder-vote?utm_source=marketbeat.com&utm_medium=referral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Creative Medical Technology stock logo

Creative Medical Technology NASDAQ:CELZ

$0.92 -0.03 (-2.79%)
Closing price 04:00 PM Eastern
Extended Trading
$0.91 -0.01 (-1.09%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Estrella Immunopharma stock logo

Estrella Immunopharma NASDAQ:ESLA

$0.44 -0.03 (-5.98%)
Closing price 04:00 PM Eastern
Extended Trading
$0.45 +0.01 (+2.95%)
As of 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Radiopharm Theranostics stock logo

Radiopharm Theranostics NASDAQ:RADX

$1.27 -0.15 (-10.56%)
Closing price 04:00 PM Eastern
Extended Trading
$1.20 -0.07 (-5.20%)
As of 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.

TScan Therapeutics stock logo

TScan Therapeutics NASDAQ:TCRX

$0.30 -0.03 (-7.86%)
Closing price 04:00 PM Eastern
Extended Trading
$0.30 +0.00 (+0.24%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas